Our suspicion was raised initially through an unusually rapid growth (< 48 h) of Aspergillus species in bronchial aspirates of three different patients. All samples were obtained during routine bronchoscopies, performed for atelectasis, respiratory deterioration or increasing inflammatory parameters. From that moment, routine galactomannan assays on serum and bronchoalveolar lavage (BAL) fluid were assessed regularly and bronchoscopy-guided biopsies of suspicious tracheobronchial lesions were obtained whenever present. Unfortunately, computed tomography (CT) scanning was deemed unfeasible in some patients due to extreme hypoxia or difficult mechanical ventilation and whenever performed, the distinction between COVID-19 and Aspergillus lesions proved complex.